Back to Search
Start Over
Gilead Sciences, Compugen ink licence deal for novel pre-clinical immunotherapy programme
- Source :
- PharmaBiz. December 21, 2023
- Publication Year :
- 2023
-
Abstract
- Gilead Sciences, Inc. an American biopharmaceutical company headquartered in Foster City, California, has announced an exclusive licence deal with Compugen Ltd, a clinical-stage cancer immunotherapy company and a pioneer in [...]
- Subjects :
- Gilead Sciences Inc. -- Licensing agreements
Compugen Ltd. -- Licensing agreements
Biological products industry -- Licensing agreements
Biological products -- Licensing agreements
Protein binding
Biotechnology industry -- Licensing agreements
Cancer -- Care and treatment
Company licensing agreement
Pharmaceuticals and cosmetics industries
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.776877080